AstraZeneca launches Brilinta adherence effort
Enrollees will get multichannel support services, including “Access My Brilinta,” which offers “time-saving prescription access and affordability information” to patients and providers alike, said the company.
The program, said AstraZeneca, was designed to address patient preference for how they receive medical info as they transition from hospital to home. The company conducted a patient survey finding that patients with Acute Coronary Syndrome want more info about their medications across multiple channels.
“With over one million people diagnosed with ACS every year, there is an ever increasing need for additional tools and resources that can help patients and their caregivers learn about and understand ACS,” said AstraZeneca VP for global medical affairs James Ferguson, MD. “These materials may help patients maintain their medication regimen.”
The program is built around key transition points, dubbed Learning, Reinforcement and Re-education.
Brilinta was approved in the US in July of 2011 and competes with Plavix.